Dyne Therapeutics (NASDAQ:DYN) Hits New 1-Year Low – Here’s Why

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $13.08 and last traded at $13.33, with a volume of 13398 shares traded. The stock had previously closed at $13.52.

Analyst Ratings Changes

DYN has been the topic of several research analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Robert W. Baird assumed coverage on Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 price target on the stock. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Friday, January 10th. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Trading Up 0.9 %

The company’s 50-day moving average is $19.76 and its 200-day moving average is $29.93. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -3.95 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the transaction, the insider now owns 201,685 shares of the company’s stock, valued at $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,289 shares of company stock valued at $580,592 over the last ninety days. 20.77% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DYN. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the third quarter valued at $34,000. Point72 DIFC Ltd bought a new stake in Dyne Therapeutics in the third quarter valued at approximately $36,000. US Bancorp DE increased its position in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the period. Values First Advisors Inc. acquired a new position in shares of Dyne Therapeutics in the 3rd quarter worth approximately $62,000. Finally, KBC Group NV increased its position in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after buying an additional 751 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.